Current Computer-Aided Drug Design

metrics 2024

Advancing Drug Discovery Through Computational Innovation

Introduction

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

Metrics 2024

SCIMAGO Journal Rank0.28
Journal Impact Factor1.50
Journal Impact Factor (5 years)1.50
H-Index32
Journal IF Without Self1.50
Eigen Factor0.00
Normal Eigen Factor0.09
Influence0.18
Immediacy Index0.70
Cited Half Life10.80
Citing Half Life7.70
JCI0.37
Total Documents699
WOS Total Citations1104
SCIMAGO Total Citations2590
SCIMAGO SELF Citations180
Scopus Journal Rank0.28
Cites / Document (2 Years)1.76
Cites / Document (3 Years)1.85
Cites / Document (4 Years)1.84

Metrics History

Rank 2024

Scopus

Drug Discovery in Pharmacology, Toxicology and Pharmaceutics
Rank #97/157
Percentile 38.22
Quartile Q3
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #121/178
Percentile 32.02
Quartile Q3

IF (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 57/72
Percentile 21.50
Quartile Q4
COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS
Rank 126/169
Percentile 25.70
Quartile Q3

JCI (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 60/72
Percentile 16.67
Quartile Q4
COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS
Rank 128/169
Percentile 24.26
Quartile Q4

Quartile History

Similar Journals

Chemical Biology & Drug Design

Fostering breakthroughs in molecular medicine and drug design.
Publisher: WILEYISSN: 1747-0277Frequency: 12 issues/year

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

CHEMICAL & PHARMACEUTICAL BULLETIN

Exploring the dynamic intersection of chemical sciences and pharmaceuticals.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0009-2363Frequency: 12 issues/year

CHEMICAL & PHARMACEUTICAL BULLETIN, published by the Pharmaceutical Society of Japan, has been a cornerstone in the fields of chemistry, drug discovery, and medicine since its inception in 1958. With an ISSN of 0009-2363, this esteemed journal offers a platform for the dissemination of innovative research and critical insights contributing to these dynamic disciplines. Housed in Tokyo, Japan, it is strategically poised to bridge the gap between chemical sciences and pharmaceutical applications. Although the journal operates under a traditional subscription model and does not currently offer open access, it maintains a solid reputation, evidenced by its Q3 category rankings in multiple relevant fields and its percentile positions in Scopus, specifically 48th in General Chemistry and 30th in Drug Discovery. Researchers, professionals, and students alike will find invaluable resources within its pages, as it diligently covers shifting paradigms and emerging methodologies critical to advancing both theoretical understanding and practical applications in the pharmaceutical realm.

Molecular Informatics

Advancing the Frontiers of Molecular Science
Publisher: WILEY-V C H VERLAG GMBHISSN: 1868-1743Frequency: 12 issues/year

Molecular Informatics is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to advancing the fields of computational analysis and molecular modeling. As a key resource in the realms of Computer Science Applications, Drug Discovery, Molecular Medicine, Organic Chemistry, and Structural Biology, this journal is recognized for its significant contributions and is ranked in the Q2 and Q3 categories across multiple disciplines, positioning it among the leading journals for researchers and academics. With an impressive track record since its inception in 2010 and converging its contributions until 2024, Molecular Informatics aims to bridge the gap between computational techniques and biological applications, promoting interdisciplinary collaboration and innovation. Accessible to a global audience, the journal reflects a commitment to advancing science through open access options, making cutting-edge research available to students, professionals, and decision-makers alike. This journal serves as an indispensable platform for disseminating high-quality research and fostering the development of new theoretical and practical frameworks in molecular informatics.

Letters in Drug Design & Discovery

Exploring New Horizons in Molecular Medicine
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1808Frequency: 12 issues/year

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

Current Research in Structural Biology

Connecting Researchers to the Latest in Structural Biology
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

Current Research in Structural Biology, published by Elsevier, is a pioneering Open Access journal that has rapidly gained prominence since its inception in 2019. With a focus on advancing the understanding of molecular and structural biology, this journal provides a platform for researchers and professionals to publish groundbreaking findings that contribute to the field's ongoing development. With a commendable Q2 ranking in both Molecular Biology and Structural Biology categories for 2023, it serves as a vital resource for the community, ensuring accessibility to high-quality research. The journal is indexed in Scopus, showcasing its significant impact and relevance, particularly with a ranking of #26/49 in the Structural Biology discipline. Located in the heart of the Netherlands, Current Research in Structural Biology not only fosters academic discourse but also encourages collaborative research efforts in addressing critical biological questions. Whether you are a researcher, student, or industry professional, this journal is essential for staying abreast of the latest advancements and trends in structural biology.

Future Journal of Pharmaceutical Sciences

Exploring the Future of Drug Science and Healthcare Solutions
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

Records of Natural Products

Bridging Nature and Innovation in Drug Research
Publisher: ACG PUBLICATIONSISSN: 1307-6167Frequency: 6 issues/year

Records of Natural Products is a distinguished journal focused on the dynamic fields of Drug Discovery, Organic Chemistry, Pharmacology, and Plant Science. Published by ACG PUBLICATIONS in Turkey, this journal serves as a vital platform for disseminating innovative research findings and advancements in natural product studies. With its convergence spanning from 2009 to 2024, Records of Natural Products holds a commendable position in the academic realm, featuring a 2023 Q3 ranking in Drug Discovery and Organic Chemistry, alongside a notable Q2 ranking in Plant Science. Despite its current lack of open access, the journal is committed to providing quality content that enriches the understanding of natural products and their potential applications. Researchers and professionals alike can benefit from the journal's insights, which not only contribute to scientific knowledge but also facilitate advancements in pharmaceuticals and sustainable practices. By exploring the rich tapestry of natural product research, this journal underscores its importance as a leading resource for professionals dedicated to enhancing the efficacy and application of natural compounds.

MEDICINAL RESEARCH REVIEWS

Advancing the Frontiers of Therapeutic Innovation
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

NATURAL PRODUCT RESEARCH

Connecting Nature and Science for a Sustainable Future
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-6419Frequency: 24 issues/year

NATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.

BIOORGANIC & MEDICINAL CHEMISTRY

Transforming Therapeutics with Cutting-Edge Chemistry
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0968-0896Frequency: 24 issues/year

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.